Absorption, Distribution and Excretion
Cefadroxil is well absorbed orally; food does not affect its absorption. Over 90% of the drug is excreted unchanged in the urine within 24 hours. Cefadroxil has been detected in the placenta and breast milk. Biological Half-Life 1.5 hours

Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation
Limited information suggests that the concentration of cefadroxil in breast milk is low and is not expected to have adverse effects on breastfed infants. There are reports that cephalosporins occasionally disrupt the infant's gut microbiota, leading to diarrhea or thrush, but these effects have not been fully assessed. Cefadroxil is safe for use by breastfeeding women.
◉ Effects on Breastfed Infants
No published information found as of the revision date.
◉ Effects on Lactation and Breast Milk
No published information found as of the revision date.

---

Protein Binding
The protein binding rate of cefadroxil was 28.1%, determined using ultrafiltration.

Cefadroxil is a cephalosporin antibiotic with a methyl group at position 3 and a (2R)-2-amino-2-(4-hydroxyphenyl)acetamide group at positions 7 of its cephalosporin skeleton. It is an antibacterial drug and the conjugate acid of cefadroxil (1-). Cefadroxil is a long-acting, broad-spectrum, water-soluble cefadroxil derivative. Anhydrous cefadroxil is a cephalosporin antibacterial drug. The effects of cefadroxil in the Chinese honeybee (Apis cerana) have been reported, and relevant data are available. Cefadroxil is a semi-synthetic β-lactam first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil can bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. Penicillin-binding proteins (PBPs) are enzymes involved in the final stages of bacterial cell wall assembly and in the remodeling of cell walls during bacterial growth and division. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of bacterial cell walls. This leads to weakening of the bacterial cell wall and ultimately cell lysis. Anhydrous cefadroxil is the anhydrous form of cefadroxil, a semi-synthetic first-generation cephalosporin with antibacterial activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. PBPs are enzymes involved in the final stages of bacterial cell wall assembly and in remodeling the cell wall during bacterial growth and division. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of bacterial cell walls. This leads to weakening of the bacterial cell wall and cell lysis. A long-acting, broad-spectrum, water-soluble cefadroxil derivative. See also: Cefadroxil monohydrate (note moved to). Drug Indications This drug is indicated for the treatment of infections caused by the following pathogens (skin, urinary tract, ear, nose, and throat): Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus, Streptococcus pyogenes (Group A β-hemolytic streptococci), Escherichia coli, Proteus mirabilis, Klebsiella spp., coagulase-negative staphylococci, and Streptococcus pyogenes. FDA Label Mechanism of Action Like all β-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located within the bacterial cell wall, thereby inhibiting the third (and final) stage of bacterial cell wall synthesis. Subsequently, bacterial cell wall autolysins (such as autolysins) mediate cell lysis; cefadroxil may interfere with autolysin inhibitors. Pharmacodynamics Cefadroxil is a first-generation cephalosporin antibiotic used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis.

C16H17N3O5S

363.39

363.088

50370-12-2

Cefadroxil hydrate;66592-87-8;Cefadroxil-d4 hydrate;1426174-38-0;Cefadroxil-d4 trifluoroacetate

47965

White to off-white solid powder

1.6±0.1 g/cm3

789.9±60.0 °C at 760 mmHg

197°C (rough estimate)

431.5±32.9 °C

0.0±2.9 mmHg at 25°C

1.728

-0.09

4

7

4

25

629

3

O=C(C(N12)=C(C)CS[C@]2([H])[C@H](NC([C@H](N)C3=CC=C(O)C=C3)=O)C1=O)O

BOEGTKLJZSQCCD-UEKVPHQBSA-N

InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1

(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Cephadroxil; Cefadroxil anhydrous; Cefadroxil

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

H2O : ~9.17 mg/mL (~25.23 mM)
DMSO : ~5 mg/mL (~13.76 mM)

Solubility in Formulation 1: 4.55 mg/mL (12.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).

---

 (Please use freshly prepared in vivo formulations for optimal results.)